Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/v13122502 http://scihub22266oqcxt.onion/10.3390/v13122502 34960772!8706629!34960772     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Viruses 2021 ; 13 (12): ä Nephropedia Template TP {{tp|p=34960772|t=2021. Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy |pdf=|usr=}}{{34960772}} gab.com Text Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy JO: Viruses http://www.kidney.de/pget.php?&tw=1&pmid=34960772 #FOAvip Gene therapy is currently in the public spotlight. Several gene therapy products, including oncolytic virus (OV), which predominantly replicates in and kills cancer cells, and COVID-19 vaccines have recently been commercialized. Recombinant adenoviruses, including replication-defective adenoviral vector and conditionally replicating adenovirus (CRA; oncolytic adenovirus), have been extensively studied and used in clinical trials for cancer and vaccines. Here, we review the biology of wild-type adenoviruses, the methodological principle for constructing recombinant adenoviruses, therapeutic applications of recombinant adenoviruses, and new technologies in pluripotent stem cell (PSC)-based regenerative medicine. Moreover, this article describes the technology platform for efficient construction of diverse "CRAs that can specifically target tumors with multiple factors" (m-CRAs). This technology allows for modification of four parts in the adenoviral E1 region and the subsequent insertion of a therapeutic gene and promoter to enhance cancer-specific viral replication (i.e., safety) as well as therapeutic effects. The screening study using the m-CRA technology successfully identified survivin-responsive m-CRA (Surv.m-CRA) as among the best m-CRAs, and clinical trials of Surv.m-CRA are underway for patients with cancer. This article also describes new recombinant adenovirus-based technologies for solving issues in PSC-based regenerative medicine. Twit Text FOAVip Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy ????Viruses http://www.kidney.de/pget.php?&tw=1&pmid=34960772 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34960772 #FOAvip English Wikipedia <ref>{{Cite pmid|34960772}}</ref> Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy #MMPMID34960772 Watanabe M; Nishikawaji Y; Kawakami H; Kosai KI Viruses 2021[Dec]; 13 (12): ä PMID34960772show ga Gene therapy is currently in the public spotlight. Several gene therapy products, including oncolytic virus (OV), which predominantly replicates in and kills cancer cells, and COVID-19 vaccines have recently been commercialized. Recombinant adenoviruses, including replication-defective adenoviral vector and conditionally replicating adenovirus (CRA; oncolytic adenovirus), have been extensively studied and used in clinical trials for cancer and vaccines. Here, we review the biology of wild-type adenoviruses, the methodological principle for constructing recombinant adenoviruses, therapeutic applications of recombinant adenoviruses, and new technologies in pluripotent stem cell (PSC)-based regenerative medicine. Moreover, this article describes the technology platform for efficient construction of diverse "CRAs that can specifically target tumors with multiple factors" (m-CRAs). This technology allows for modification of four parts in the adenoviral E1 region and the subsequent insertion of a therapeutic gene and promoter to enhance cancer-specific viral replication (i.e., safety) as well as therapeutic effects. The screening study using the m-CRA technology successfully identified survivin-responsive m-CRA (Surv.m-CRA) as among the best m-CRAs, and clinical trials of Surv.m-CRA are underway for patients with cancer. This article also describes new recombinant adenovirus-based technologies for solving issues in PSC-based regenerative medicine. |*Genetic Therapy[MESH] |Adenoviridae Infections/*virology[MESH] |Adenoviridae/*genetics/*physiology[MESH] |Animals[MESH] |COVID-19 Vaccines[MESH] |COVID-19/*prevention & control[MESH] |Cell Line, Tumor[MESH] |Gene Expression[MESH] |Genetic Vectors[MESH] |Humans[MESH] |Immunotherapy[MESH] |Oncolytic Viruses/genetics[MESH] |Pluripotent Stem Cells[MESH] |Promoter Regions, Genetic[MESH] |SARS-CoV-2[MESH] |Survivin[MESH]Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Ge(epmc).pdf DeepDyve Pubget Overpricing